Advertisement

Adenosine pp 621-656 | Cite as

Anatomical Distribution of Nucleoside System in the Human Brain and Implications for Therapy

  • Zsolt KovácsEmail author
  • Arpád Dobolyi
Chapter

Abstract

Nucleosides have a wide range of physiological and pathophysiological roles in the human brain as modulators of a variety of neural functions. For example, adenosine, inosine, guanosine, and uridine participate in the mechanisms underlying memory, cognition, sleep, pain, depression, schizophrenia, epilepsy, Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Consequently, increasing attention is now being given to the specific role of nucleosides in physiological and pathological processes in the human brain. Different elements of nucleoside system, including nucleoside concentrations, metabolic enzyme activity, and expression of nucleoside transporters and receptors, may be changed under normal and pathological conditions. The alterations suggest that interlinked elements of the nucleoside system are functioning in a tightly concerted manner.

Nucleoside levels, activity of nucleoside metabolic enzymes, and expression of nucleoside transporters and receptors are unevenly distributed in the brain, suggesting that nucleosides have different roles in functionally distinct human brain areas. The aim of this chapter is to summarize our present knowledge of the anatomical distribution of nucleoside system in the human brain, placing emphasis on potential therapeutic pharmacological strategies.

Keywords

Nucleosides Anatomical distribution of nucleoside system Human brain diseases and therapy 

Abbreviations

5′NT

5′-Nucleotidases

A1 receptor/A2A receptor/A2B receptor/A3 receptor

A1R/A2AR/A2BR/A3R subtype of adenosine receptors

AC

Adenylate cyclase

ADA

Adenosine deaminase

Ade

Adenine

ADK

Adenosine kinase

Ado

Adenosine

AMP

Adenosine monophosphate

CDP-choline

Cytidine diphosphocholine

cN

Cytoplasmic 5′-nucleotidases

CNS

Central nervous system

CNT transporters

Concentrative nucleoside transporters

CNT1/CNT2/CNT3 transporters

CNT1/CNT2/CNT3 subtype of concentrative nucleoside transporters

Cyd

Cytidine

EC

Extracellular

ENT transporters

Equilibrative nucleoside transporters

ENT1/ENT2/ENT3/ENT4 transporters

ENT1/ENT2/ENT3/ENT4 subtype of equilibrative nucleoside transporters

“es” nucleoside transporters

Equilibrative, NBTI sensitive type of ENT transporters

GABA

γ-Aminobutyric acid

GDA

Guanine deaminase

GMP

Guanosine monophosphate

Gn

Guanine

Guo

Guanosine

Hyp

Hypoxanthine

IMP

Inosine monophosphate

Ino

Inosine

NBTI

S-(4-nitrobenzyl)-6-thioinosine

PLC

Phospholipase C

PNP

Purine nucleoside phosphorylase

Urd

Uridine

Xn

Xanthine

Notes

Acknowledgments

This work was supported by the Scientific Foundation of NYME SEK/NYME SEK TTK (2010–2011) Hungary (Zsolt Kovács) and the OTKA NNF2 85612 Research Grant as well as the Bolyai János Grant of the Hungarian Academy of Sciences (Arpád Dobolyi).

Conflict of interest: All authors declare no conflicts of interest.

References

  1. Agnati LF, Fuxe K, Ruggeri M, Merlo Pich E, Benfenati F, Volterra V, Ungerstedt U, Zini I (1989) Effects of chronic treatment with uridine on striatal dopamine release and dopamine related behaviours in the absence or the presence of chronic treatment with haloperidol. Neurochem Int 15:107–113PubMedCrossRefGoogle Scholar
  2. Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A (2000) Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther 25:131–137PubMedCrossRefGoogle Scholar
  3. Akhondzadeh S, Safarcherati A, Amini H (2005) Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 29:253–259PubMedCrossRefGoogle Scholar
  4. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M (2006) Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 8:485–489PubMedCrossRefGoogle Scholar
  5. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK (2005) Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9:463–484PubMedCrossRefGoogle Scholar
  6. Arias-Menendez L (2002) Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23:381–388CrossRefGoogle Scholar
  7. Baldo BA, Koob GF, Markou A (1999) Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J Neurosci 19:11017–11026PubMedGoogle Scholar
  8. Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216–224PubMedCrossRefGoogle Scholar
  9. Baldwin SA, Yao SYM, Hyde RJ, Ng AML, Foppolo S, Barnes K, Ritzel MWL, Cass CE, Young JD (2005) Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280:15880–15887PubMedCrossRefGoogle Scholar
  10. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L, Tellez J, Ritzel MW, Claycomb WC, Cass CE, Young JD, Billeter-Clark R, Boyett MR, Baldwin SA (2006) Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99:510–519PubMedCrossRefGoogle Scholar
  11. Barraco RA, Swanson TH, Phillis JW, Berman RF (1984) Anticonvulsant effects of adenosine analogues on amygdaloid-kindled seizures in rats. Neurosci Lett 46:317–322PubMedCrossRefGoogle Scholar
  12. Barrett RJ, Lamson MJ, Johnson J, Smith WB (2005) Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J Nucl Cardiol 12:166–171PubMedCrossRefGoogle Scholar
  13. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA (2005) A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30:891–900PubMedCrossRefGoogle Scholar
  14. Bender E, Buist A, Jurzak M, Langlois X, Baggerman G, Verhasselt P, Ercken M, Guo HQ, Wintmolders C, Van den Wyngaert I, Van Oers I, Schoofs L, Luyten W (2002) Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc Natl Acad Sci USA 99:8573–8578PubMedCrossRefGoogle Scholar
  15. Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301–309PubMedCrossRefGoogle Scholar
  16. Berne RM, Rubio R, Curnish RR (1974) Release of adenosine from ischemic brain: effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ Res 35:262–271CrossRefGoogle Scholar
  17. Bertram EH (2009) Temporal lobe epilepsy: where do the seizures really begin? Epilepsy Behav 14(Suppl 1):32–37PubMedCrossRefGoogle Scholar
  18. Beukers MW, Chang LC, von Frijtag Drabbe Kunzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, Ijzerman AP (2004) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707–3709PubMedCrossRefGoogle Scholar
  19. Bjerring PN, Hauerberg J, Jørgensen L, Frederiksen HJ, Tofteng F, Hansen BA, Larsen FS (2010) Brain hypoxanthine concentration correlates to lactate/pyruvate ratio but not intracranial pressure in patients with acute liver failure. J Hepatol 53:1054–1058PubMedCrossRefGoogle Scholar
  20. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN (2003) Adenosine receptors and Huntington’s disease: implications for pathogenesis and therapeutics. Lancet Neurol 2:366–374PubMedCrossRefGoogle Scholar
  21. Boison D (2005) Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11:25–36PubMedCrossRefGoogle Scholar
  22. Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249–262PubMedCrossRefGoogle Scholar
  23. Boison D (2011) Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem 11:1068–1086PubMedCrossRefGoogle Scholar
  24. Boison D, Singer P, Shen HY, Feldon J, Yee BK (2012) Adenosine hypothesis of schizophrenia-Opportunities for pharmacotherapy. Neuropharmacology 62:1527–1543Google Scholar
  25. Borbely AA, Tobler I (1989) Endogenous sleep-promoting substances and sleep regulation. Physiol Rev 69:605–670PubMedGoogle Scholar
  26. Borrmann T, Abdelrahman A, Volpini R, Lambertucci C, Alksnis E, Gorzalka S, Knospe M, Schiedel AC, Cristalli G, Müller CE (2009) Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem 52:5974–5989PubMedCrossRefGoogle Scholar
  27. Bowley MP, Drevets WC, Öngür D, Price JL (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52:404–412PubMedCrossRefGoogle Scholar
  28. Brauch RA, Adnan El-Masri M, Parker JC Jr, El-Mallakh RS (2006) Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord 91:87–90PubMedCrossRefGoogle Scholar
  29. Breckenridge A (2005) Pharmacology of drugs for HIV. Medicine 33:30–31CrossRefGoogle Scholar
  30. Brundege JM, Williams JT (2002) Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J Neurophysiol 87:1369–1375PubMedGoogle Scholar
  31. Burnstock G, Fredholm BB, Verkhratsky A (2011) Adenosine and ATP receptors in the brain. Curr Top Med Chem 11:973–1011PubMedCrossRefGoogle Scholar
  32. Bzowska A, Kulikowska E, Shugar D (2000) Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Therapeut 88:349–425CrossRefGoogle Scholar
  33. Cansev M (2006) Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev 52:389–397PubMedCrossRefGoogle Scholar
  34. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ (2008) Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson’s disease. Neurosci Res 62:206–209PubMedCrossRefGoogle Scholar
  35. Castane A, Soria G, Ledent C, Maldonado R, Valverde O (2006) Attenuation of nicotine-induced rewarding effects in A2A knockout mice. Neuropharmacology 51:631–640PubMedCrossRefGoogle Scholar
  36. Ceballos G, Tuttle JB, Rubio R (1994) Differential distribution of purine metabolizing enzymes between glia and neurons. J Neurochem 62:1144–1153PubMedCrossRefGoogle Scholar
  37. Ceruti S, Franceschi C, Barbieri D, Malorni W, Camurri A, Giammarioli AM, Ambrosini A, Racagni G, Cattabeni F, Abbracchio MP (2000) Apoptosis induced by 2-chloro-adenosine and 2-chloro-2’-deoxy-adenosine in a human astrocytoma cell line: differential mechanisms and possible clinical relevance. J Neurosci Res 60:388–400PubMedCrossRefGoogle Scholar
  38. Chang R, Algird A, Bau C, Rathbone MP, Jiang S (2008) Neuroprotective effects of guanosine on stroke models in vitro and in vivo. Neurosci Lett 431:101–105PubMedCrossRefGoogle Scholar
  39. Chen TH, Wang MF, Liang YF, Komatsu T, Chan YC, Chung SY, Yamamoto S (2000) A nucleoside-nucleotide mixture may reduce memory deterioration in old senescence-accelerated mice. J Nutr 130:3085–3089PubMedGoogle Scholar
  40. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 21:RC143PubMedGoogle Scholar
  41. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y (2005) CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model. J Neurochem 93:310–320PubMedCrossRefGoogle Scholar
  42. Ciccarelli R, Ballerini P, Sabatino G, Rathbone MP, D’Onofrio M, Caciagli F, Di Iorio P (2001) Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci 19:395–414PubMedCrossRefGoogle Scholar
  43. Connolly GP, Duley JA (1999) Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 20:218–225PubMedCrossRefGoogle Scholar
  44. Cornfield LJ, Hu S, Hurt SD, Sills MA (1992) [3 H]2-phenylaminoadenosine ([3 H]CV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther 263:552–561PubMedGoogle Scholar
  45. Cunha RA (2005) Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1:111–134PubMedCrossRefGoogle Scholar
  46. Cunha RA, Johansson B, Fredholm BB, Ribeiro JA, Sebastiao AM (1995) Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Lett 196:41–44PubMedCrossRefGoogle Scholar
  47. Curros-Criado MM, Herrero JF (2005) The antinociceptive effects of the systemic adenosine A1 receptor agonist CPA in the absence and in the presence of spinal cord sensitization. Pharmacol Biochem Behav 82:721–726PubMedCrossRefGoogle Scholar
  48. D’Alimonte I, D’Auro M, Citraro R, Biagioni F, Jiang S, Nargi E, Buccella S, Di Iorio P, Giuliani P, Ballerini P, Caciagli F, Russo E, De Sarro G, Ciccarelli R (2009) Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur J Neurosci 30:1023–1035PubMedCrossRefGoogle Scholar
  49. Dall’Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138:1207–1209PubMedCrossRefGoogle Scholar
  50. Dall’Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203:241–245PubMedCrossRefGoogle Scholar
  51. Datta S, Maclean RR (2007) Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. Neurosci Biobehav Rev 31:775–824PubMedCrossRefGoogle Scholar
  52. Dawson DM (1971) Absence of guanine deaminase from cerebellum. Neurology 21:621–626PubMedCrossRefGoogle Scholar
  53. De Clercq E (2004) Antiviral drugs in current clinical use. J Clin Virol 30:115–133PubMedCrossRefGoogle Scholar
  54. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307–320PubMedCrossRefGoogle Scholar
  55. De Clercq E (2011) A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 51:1–24PubMedCrossRefGoogle Scholar
  56. De Mattia E, Toffoli G (2009) C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 45:1333–1351PubMedCrossRefGoogle Scholar
  57. De Mendonca A, Sebastiao AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport 6:1097–1100PubMedCrossRefGoogle Scholar
  58. De Oliveira DL, Horn JF, Rodrigues JM, Frizzo ME, Moriguchi E, Souza DO, Wofchuk S (2004) Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. Brain Res 1018:48–54PubMedCrossRefGoogle Scholar
  59. Deckert J, Abel F, Kunig G, Hartmann J, Senitz D, Maier H, Ransmayr G, Riederer P (1998) Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity. Neurosci Lett 244:1–4PubMedCrossRefGoogle Scholar
  60. Deutsch SI, Long KD, Rosse RB, Mastropaolo J, Eller J (2005) Hypothesized deficiency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome. Clin Neuropharmacol 28:28–37PubMedCrossRefGoogle Scholar
  61. Di Iorio P, Ballerini P, Traversa U, Nicoletti F, D’Alimonte I, Kleywegt S, Werstiuk ES, Rathbone MP, Caciagli F, Ciccarelli R (2004) The antiapoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes. Glia 46:356–368PubMedCrossRefGoogle Scholar
  62. Dietrich WD (1998) Neurobiology of stroke. Int Rev Neurobiol 42:55–101PubMedCrossRefGoogle Scholar
  63. Dobolyi A, Szikra T, Kekesi AK, Kovacs Z, Juhasz G (1999) Uridine is released by depolarization and inhibits unit activity in the rat hippocampus. Neuroreport 10:3049–3053PubMedCrossRefGoogle Scholar
  64. Dobolyi A, Reichart A, Szikra T, Nyitrai G, Kekesi KA, Juhasz G (2000) Sustained depolarisation induces changes in the extracellular concentrations of purine and pyrimidine nucleosides in the rat thalamus. Neurochem Int 37:71–79PubMedCrossRefGoogle Scholar
  65. Dobolyi A, Juhasz G, Kovacs Z, Kardos J (2011) Uridine function in the central nervous system. Curr Top Med Chem 11:1058–1067PubMedCrossRefGoogle Scholar
  66. Durieux PF, Schiffmann SN, de Kerchove d’Exaerde A (2011) Targeting neuronal populations of the striatum. Front Neuroanat 5:40PubMedCrossRefGoogle Scholar
  67. Dwivedi C, Harbison RD (1975) Anticonvulsant activities of delta-8 and delta-9 tetrahydrocannabinol and uridine. Toxicol Appl Pharmacol 31:452–458PubMedCrossRefGoogle Scholar
  68. Eells JT, Spector R (1983) Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res 8:1451–1457PubMedCrossRefGoogle Scholar
  69. Ekonomou A, Angelatou F, Vergnes M, Kostopoulos G (1998) Lower density of A1 adenosine receptors in nucleus reticularis thalami in rats with genetic absence epilepsy. Neuroreport 9:2135–2140PubMedCrossRefGoogle Scholar
  70. Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901–1910PubMedCrossRefGoogle Scholar
  71. Erion MD, Ugarkar BG, Dare J, Castellino AJ, Fujitaki JM, Dixon R, Appleman JR, Wiesner JB (1997) Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleos Nucleot 16:1013–1021CrossRefGoogle Scholar
  72. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16:85–91PubMedGoogle Scholar
  73. Farabegoli C, Merlo Pich E, Cimino M, Agnati LF, Fuxe K (1988) Chronic uridine treatment reduces the level of [3 H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Acta Physiol Scand 132:209–216PubMedCrossRefGoogle Scholar
  74. Fastbom J, Pazos A, Probst A, Palacios JM (1986) Adenosine A1 receptors is human brain: characterisation and autoradiographic visualization. Neurosci Lett 65:127–132PubMedCrossRefGoogle Scholar
  75. Fastbom J, Pazos A, Palacios JM (1987) The distribution of adenosine A1 receptors and 5’-nucleotidase is the brain of some commonly used experimental animals. Neuroscience 22:813–826PubMedCrossRefGoogle Scholar
  76. Fava M (2003) The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 64(Suppl 13):26–29PubMedGoogle Scholar
  77. Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D (2006) Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200:184–190PubMedCrossRefGoogle Scholar
  78. Fernández JR, Sweet ES, Welsh WJ, Firestein BL (2010) Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. Bioorg Med Chem 18:6748–6755PubMedCrossRefGoogle Scholar
  79. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482–487PubMedCrossRefGoogle Scholar
  80. Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I (2007) Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog Neurobiol 83:332–347PubMedCrossRefGoogle Scholar
  81. Fields RD, Burnstock G (2006) Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 7:423–436PubMedCrossRefGoogle Scholar
  82. Firestein BL, Brenman JE, Aoki C, Sanchez-Perez AM, El-Husseini AE, Bredt DS (1999) Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting. Neuron 24:659–672PubMedCrossRefGoogle Scholar
  83. Franklin A, Blanden RV (2007) Potential inhibition of somatic hypermutation by nucleoside analogues. Mol Immunol 44:666–669PubMedCrossRefGoogle Scholar
  84. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133PubMedGoogle Scholar
  85. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552PubMedGoogle Scholar
  86. Frizzo ME, Lara DR, Prokopiuk Ade S, Vargas CR, Salbego CG, Wajner M, Souza DO (2002) Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. Cell Mol Neurobiol 22:353–363PubMedCrossRefGoogle Scholar
  87. Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415–424PubMedCrossRefGoogle Scholar
  88. Garakani A, Mathew SJ, Charney DS (2006) Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73:941–949PubMedGoogle Scholar
  89. Geiger JD, Nagy JI (1986) Distribution of adenosine deaminase activity in rat brain and spinal cord. J Neurosci 6:2707–2714PubMedGoogle Scholar
  90. Gerevich Z, Wirkner K, Illes P (2002) Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. Eur J Pharmacol 451:161–164PubMedCrossRefGoogle Scholar
  91. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M, Johansson B (2002) Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 16:547–550PubMedCrossRefGoogle Scholar
  92. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002) BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105:1348–1353PubMedCrossRefGoogle Scholar
  93. Gracia E, Cortés A, Meana JJ, García-Sevilla J, Herhsfield MS, Canela EI, Mallol J, Lluís C, Franco R, Casadó V (2008) Human adenosine deaminase as an allosteric modulator of human A(1) adenosine receptor: abolishment of negative cooperativity for [H](R)-pia binding to the caudate nucleus. J Neurochem 107:161–170PubMedCrossRefGoogle Scholar
  94. Griffith GA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153–181PubMedCrossRefGoogle Scholar
  95. Guillén-Gómez E, Calbet M, Casado J, de Lecea L, Soriano E, Pastor-Anglada M, Burgaya F (2004) Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. J Neurochem 90:883–893PubMedCrossRefGoogle Scholar
  96. Hagberg H, Andersson P, Lacarewicz J, Jacobson I, Butcher S, Sandberg M (1987) Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J Neurochem 49:227–231PubMedCrossRefGoogle Scholar
  97. Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29:558–565PubMedCrossRefGoogle Scholar
  98. Hanley SP, Hampton JR (1983) Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J 4:889–893PubMedGoogle Scholar
  99. Harper DG, Stopa EG, Kuo-Leblanc V, McKee AC, Asayama K, Volicer L, Kowall N, Satlin A (2008) Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain 131:1609–1617PubMedCrossRefGoogle Scholar
  100. Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, Minagar A (2009) Movement disorders. Med Clin North Am 93:371–388PubMedCrossRefGoogle Scholar
  101. Haskó G, Sitkovsky MV, Szabó C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25:152–157PubMedCrossRefGoogle Scholar
  102. Haskó G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511–516PubMedCrossRefGoogle Scholar
  103. Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61–76PubMedCrossRefGoogle Scholar
  104. Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61:286–287CrossRefGoogle Scholar
  105. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221–229PubMedCrossRefGoogle Scholar
  106. Headrick JP, Peart JN, Reichelt ME, Haseler LJ (2011) Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim Biophys Acta 1808:1413–1428PubMedCrossRefGoogle Scholar
  107. Heinricher MM, Tavares I, Leith JL, Lumb BM (2009) Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev 60:214–225PubMedCrossRefGoogle Scholar
  108. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ (2005) Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46:2076–2078CrossRefGoogle Scholar
  109. Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, Pond AJ, Hadjtahar A, Belanger N, Gregoire L, Dare A, Neustadt BR, Stamford AW, Hunter JC (2010) Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 225:384–390PubMedCrossRefGoogle Scholar
  110. Holguin S, Martinez J, Chow C, Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22:3938–3946PubMedCrossRefGoogle Scholar
  111. Honda K, Komoda Y, Nishida S, Nagasaki H, Higashi A, Uchizono K, Inoue S (1984) Uridine as an active component of sleep-promoting substance: its effects on nocturnal sleep in rats. Neurosci Res 1:243–252PubMedCrossRefGoogle Scholar
  112. Honda K, Okano Y, Komoda Y, Inoue S (1985) Sleep-promoting effects of intraperitoneally administered uridine in unrestrained rats. Neurosci Lett 62:137–141PubMedCrossRefGoogle Scholar
  113. Huang ZL, Urade Y, Hayaishi O (2011) The role of adenosine in the regulation of sleep. Curr Top Med Chem 11:1047–1057PubMedCrossRefGoogle Scholar
  114. Inoue S (1986) Sleep and sleep substances. Brain Dev 8:469–473PubMedCrossRefGoogle Scholar
  115. Ipata PL, Camici M, Micheli V, Tozzi MG (2011) Metabolic network of nucleosides in the brain. Curr Top Med Chem 11:909–922PubMedCrossRefGoogle Scholar
  116. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184–191PubMedCrossRefGoogle Scholar
  117. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247–264PubMedCrossRefGoogle Scholar
  118. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009) Adenosine, adenosine A2A antagonists, and Parkinson’s disease. Parkinsonism Relat Disord 15:406–413PubMedCrossRefGoogle Scholar
  119. Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young J, Cass CE (2001) Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40:722–731PubMedCrossRefGoogle Scholar
  120. Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedeberg’s Arch Pharmacol 355:48–56CrossRefGoogle Scholar
  121. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hårdemark A, Betsholtz C, Herlenius E, Fredholm BB (2001) Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98:9407–9412PubMedCrossRefGoogle Scholar
  122. Jurkowitz MS, Litsky ML, Browning MJ, Hohl CM (1998) Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J Neurochem 71:535–548PubMedCrossRefGoogle Scholar
  123. Kaiser SM, Quinn RJ (1999) Adenosine receptors as potential therapeutic targets. Drug Discov Today 4:542–551PubMedCrossRefGoogle Scholar
  124. Kalia M (2005) Neurobiological basis of depression: an update. Metabolism 54:24–27PubMedCrossRefGoogle Scholar
  125. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507–513PubMedCrossRefGoogle Scholar
  126. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321–327PubMedCrossRefGoogle Scholar
  127. Kékesi KA, Kovács Z, Szilágyi N, Bobest M, Szikra T, Dobolyi Á, Juhász G, Palkovits M (2006) Concentration of nucleosides and related compounds in cerebral and cerebellar cortical areas and white matter of the human brain. Cell Mol Neurobiol 26:831–842CrossRefGoogle Scholar
  128. Kimura T, Ho IK, Yamamoto I (2001) Uridine receptor: discovery and its involvement in sleep mechanism. Sleep 24:251–260PubMedGoogle Scholar
  129. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416–425PubMedCrossRefGoogle Scholar
  130. Kirmse K, Dvorzhak A, Grantyn R, Kirischuk S (2008) Developmental downregulation of excitatory GABAergic transmission in neocortical layer I via presynaptic adenosine A(1) receptors. Cereb Cortex 18:424–432PubMedCrossRefGoogle Scholar
  131. Kitagawa M, Houzen H, Tashiro K (2007) Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord 22:710–712PubMedCrossRefGoogle Scholar
  132. Kittner B, Rossner M, Rother M (1997) Clinical trials in dementia with propentofylline. Ann N Y Acad Sci 826:307–316PubMedCrossRefGoogle Scholar
  133. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine’s anxiogenic effects. Biol Psychiatry 30:973–984PubMedCrossRefGoogle Scholar
  134. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C (2001) Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav 68:797–803PubMedCrossRefGoogle Scholar
  135. Kovács Z, Dobolyi A (2011) Functions and metabolism of brain nucleosides and their metabolites. Curr Top Med Chem 11:907–908PubMedCrossRefGoogle Scholar
  136. Kovács Z, Dobolyi Á, Szikra T, Palkovits M, Juhász G (1998) Uneven regional distribution of nucleotide metabolism in human brain. Neurobiology (Bp) 6:315–321Google Scholar
  137. Kovács Z, Kékesi KA, Bobest M, Török T, Szilágyi N, Szikra T, Szepesi Z, Nyilas R, Dobolyi Á, Palkovits M, Juhász G (2005) Post mortem degradation of nucleosides in the brain: comparison of human and rat brains for estimation of in vivo concentration of nucleosides. J Neurosci Methods 148:88–93PubMedCrossRefGoogle Scholar
  138. Kovács Z, Dobolyi A, Juhász G, Kékesi AK (2010a) Nucleoside map of the human central nervous system. Neurochem Res 35:452–464PubMedCrossRefGoogle Scholar
  139. Kovács Z, Juhász G, Dobolyi A, Bobest M, Papp V, Takáts L, Kékesi KA (2010b) Gender- and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain Res Bull 81:579–584PubMedCrossRefGoogle Scholar
  140. Kovács Z, Juhász G, Palkovits M, Dobolyi A, Kékesi KA (2011) Area, age and gender dependence of the nucleoside system in the brain: a review of current literature. Curr Top Med Chem 11:1012–1033PubMedCrossRefGoogle Scholar
  141. Kowaluk EA, Jarvis MF (2000) Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 9:551–564PubMedCrossRefGoogle Scholar
  142. Lajtha A, Sershen H (2010) Heterogeneity of reward mechanisms. Neurochem Res 35:851–867PubMedCrossRefGoogle Scholar
  143. Lam P, Hong CJ, Tsai SJ (2005) Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett 378:98–101PubMedCrossRefGoogle Scholar
  144. Lara DR, Dall’Igna OP, Ghisolfi ES, Brunstein MG (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30:617–629PubMedCrossRefGoogle Scholar
  145. Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79:463–484PubMedCrossRefGoogle Scholar
  146. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674–678PubMedCrossRefGoogle Scholar
  147. Lehman NL (2002) Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11:1775–1787PubMedCrossRefGoogle Scholar
  148. Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34:28–35PubMedCrossRefGoogle Scholar
  149. Li RW, Tse CM, Man RY, Vanhoutte PM, Leung GP (2007) Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur J Pharmacol 568:75–82PubMedCrossRefGoogle Scholar
  150. Lima FO, Souza GR, Verri WA Jr, Parada CA, Ferreira SH, Cunha FQ, Cunha TM (2010) Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain 151:506–515PubMedCrossRefGoogle Scholar
  151. Linden J, Rosin DL (2006) Purinergic systems. In: Siegel G, Albers RW, Brady S, Price D (eds) Basic neurochemistry: molecular, cellular and medical aspects, 7th edn. Elsevier, Academic Press Inc., New York, USA, pp 303–316Google Scholar
  152. Linker RA, Kieseier BC, Gold R (2008) Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 29:558–565PubMedCrossRefGoogle Scholar
  153. Litsky ML, Hohl CM, Lucas JH, Jurkowitz MS (1999) Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Brain Res 821:426–432PubMedCrossRefGoogle Scholar
  154. Liu XQ, Sheng R, Qin ZH (2009) The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin 30:1071–1080PubMedCrossRefGoogle Scholar
  155. Lopes LV, Sebastiao AM, Ribeiro JA (2011) Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem 11:1087–1101PubMedCrossRefGoogle Scholar
  156. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28:35–40PubMedCrossRefGoogle Scholar
  157. Luthin DR, Linden J (1995) Comparison of A4 and A2A binding sites in striatum and COS cells transfected with adenosine A2A receptors. J Pharmacol Exp Ther 272:511–518PubMedGoogle Scholar
  158. Mangravite LM, Badagnani I, Giacomini KM (2003) Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 479:269–281PubMedCrossRefGoogle Scholar
  159. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H (2009) The treatment of multiple sclerosis with inosine. J Altern Complement Med 15:619–625PubMedCrossRefGoogle Scholar
  160. Marro PJ, Mishra OP, Delivoria-Papadopoulos M (2006) Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 1073–1074:444–450PubMedCrossRefGoogle Scholar
  161. Martini C, Daniele S, Picchetti M, Panighini A, Carlini M, Trincavelli ML, Cesari D, Da Pozzo E, Golia F, Dell’Osso L (2011) A(2A) adenosine receptor binding parameters in platelets from patients affected by pathological gambling. Neuropsychobiology 63:154–159PubMedCrossRefGoogle Scholar
  162. McGaraughty S, Cowart M, Jarvis MF, Berman RF (2005) Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 5:43–58PubMedCrossRefGoogle Scholar
  163. Melani A, De Micheli E, Pinna G, Alfieri A, Corte LD, Pedata F (2003) Adenosine extracellular levels in human brain gliomas: an intraoperative microdialysis study. Neurosci Lett 346:93–96PubMedCrossRefGoogle Scholar
  164. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31–48PubMedCrossRefGoogle Scholar
  165. Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, Bauer A (2007) Effect of aging on cerebral A1 adenosine receptors: a [18 F]CPFPX PET study in humans. Neurobiol Aging 28:1914–1924PubMedCrossRefGoogle Scholar
  166. Mielke R, Moller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B (1998) Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord 12(Suppl 2):S29–S35PubMedGoogle Scholar
  167. Moreau JL, Huber G (1999) Central adenosine A2A recetors: an overview. Brain Res Rev 31:65–82PubMedCrossRefGoogle Scholar
  168. Müller CE (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 3:445–462PubMedCrossRefGoogle Scholar
  169. Myers CS, Fisher H, Wagner GC (1994) Uridine potentiates haloperidol’s disruption of conditioned avoidance responding. Brain Res 651:194–198PubMedCrossRefGoogle Scholar
  170. Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28:429–442PubMedCrossRefGoogle Scholar
  171. Nagata H, Mimori Y, Nakamura S, Kameyama M (1984) Regional and subcellular distribution in mammalian brain of the enzymes producing adenosine. J Neurochem 42:1001–1007PubMedCrossRefGoogle Scholar
  172. Noji T, Karasawa A, Kusaka H (2004) Adenosine uptake inhibitors. Eur J Pharmacol 495:1–16PubMedCrossRefGoogle Scholar
  173. Norstrand IF, Glantz MD (1980) Topographical distribution of purine nucleoside phosphorylase in the human neuraxis. Enzyme 25:118–122PubMedGoogle Scholar
  174. Norstrand IF, Siverls VC, Libbin RM (1984) Regional distribution of adenosine deaminase in the human neuraxis. Enzyme 32:20–25PubMedGoogle Scholar
  175. O’Regan M (2005) Adenosine and the regulation of cerebral blood flow. Neurol Res 27:175–181PubMedCrossRefGoogle Scholar
  176. Öngür D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290–13295PubMedCrossRefGoogle Scholar
  177. Parkinson FE, Damaraju VL, Graham K, Yao SYM, Baldwin SA, Cass CE, Young JD (2011) Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem 11:948–972PubMedCrossRefGoogle Scholar
  178. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martinez-Picado J, Casado JF (2005) Cell entry and export of nucleoside analogues. Virus Res 107:151–164PubMedCrossRefGoogle Scholar
  179. Paul T, Pfammatter JP (1997) Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatr Cardiol 18:118–126PubMedCrossRefGoogle Scholar
  180. Pearce L, Ghosh J, Counsell A, Serracino-Inglott F (2008) Cilostazol and peripheral arterial disease. Expert Opin Pharmacother 9:2683–2690PubMedCrossRefGoogle Scholar
  181. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280:951–959PubMedCrossRefGoogle Scholar
  182. Peskind ER (1996) Neurobiology of Alzheimer’s disease. J Clin Psychiatry 57(Suppl 14):5–8PubMedGoogle Scholar
  183. Peterman C, Sanoski CA (2005) Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev 13:315–321PubMedCrossRefGoogle Scholar
  184. Pettifer KM, Kleywegt S, Bau CJ, Ramsbottom JD, Vertes E, Ciccarelli R, Caciagli F, Werstiuk ES, Rathbone MP (2004) Guanosine protects SH-SY5Y cells against beta-amyloid-induced apoptosis. Neuroreport 15:833–836PubMedCrossRefGoogle Scholar
  185. Phillips E, Newsholme EA (1979) Maximum activities, properties and distribution of 5’-nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J Neurochem 33:553–558PubMedCrossRefGoogle Scholar
  186. Piccoli F, Camarda R, Bonavita V (1971) The brain nucleotide pattern of the rat after injection of uracil, uridine and uridine phosphate. Acta Neurol (Napoli) 26:109–117Google Scholar
  187. Pinna A (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 18:1619–1631PubMedCrossRefGoogle Scholar
  188. Podgorska M, Kocbuch K, Pawelczyk T (2005) Recent advences in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52:749–758PubMedGoogle Scholar
  189. Popoli P, Blum D, Martine A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington’s disease. Prog Neurobiol 81:331–348PubMedCrossRefGoogle Scholar
  190. Porkka-Heiskanen T, Kalinchuk AV (2011) Adenosine, energy metabolism and sleep homeostasis. Sleep Med Rev 15:123–135PubMedCrossRefGoogle Scholar
  191. Radulovacki M (1985) Role of adenosine in sleep in rats. Rev Clin Basic Pharm 5:327–339PubMedGoogle Scholar
  192. Rando RF, Nguyen-Ba N (2000) Development of novel nucleoside analogues for use against drug rersisitant strains of HIV-1. Drug Discov Today 5:465–476PubMedCrossRefGoogle Scholar
  193. Ribeiro JA, Sebastiao AM, de Mendonca A (2003) Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377–392CrossRefGoogle Scholar
  194. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 69:536–545PubMedCrossRefGoogle Scholar
  195. Ritzel MWL, Ng AML, Yao SYM, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, Chen XZ, Karpinski E, Hyde RJ, Baldwin SA, Cass CE, Young JD (2001) Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914–2927PubMedCrossRefGoogle Scholar
  196. Robak T, Korycka A, Lech-Maranda E, Robak P (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14:1183–1226PubMedCrossRefGoogle Scholar
  197. Roberts CA (1973) Anticonvulsant effects of uridine: comparative analysis of metrazol and penicillin induced foci. Brain Res 55:291–308PubMedCrossRefGoogle Scholar
  198. Roberts CA, Kreisman NR, Waltman M (1974) Uridine anticonvulsant effects: selective control of nucleoside incorporation in experimental epilepsy. Epilepsia 15:479–500PubMedCrossRefGoogle Scholar
  199. Roesler R, Vianna MR, Lara DR, Izquierdo I, Schmidt AP, Souza DO (2000) Guanosine impairs inhibitory avoidance performance in rats. Neuroreport 11:2537–2540PubMedCrossRefGoogle Scholar
  200. Roos RA, Bots GT, Hermans J (1985) Neuronal nuclear membrane indentation and astrocyte/neuron ratio in Huntington’s disease. A quantitative electron microscopic study. J Hirnforsch 26:689–693PubMedGoogle Scholar
  201. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. Neuron 52:139–153PubMedCrossRefGoogle Scholar
  202. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4:346–369PubMedGoogle Scholar
  203. Saper CB (2006) Staying awake for dinner: hypothalamic integration of sleep, feeding, and circadian rhythms. Prog Brain Res 153:243–252PubMedCrossRefGoogle Scholar
  204. Saute JA, da Silveira LE, Soares FA, Martini LH, Souza DO, Ganzella M (2006) Amnesic effect of GMP depends on its conversion to guanosine. Neurobiol Learn Mem 85:206–212PubMedCrossRefGoogle Scholar
  205. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007) Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83:277–292PubMedCrossRefGoogle Scholar
  206. Schmidt AP, Lara DR, de Faria Maraschin J, da Silveira Perla A, Souza DO (2000) Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res 864:40–43PubMedCrossRefGoogle Scholar
  207. Schmidt AP, Lara DR, Souza DO (2007) Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Therapeut 116:401–416CrossRefGoogle Scholar
  208. Schmidt AP, Böhmer AE, Schallenberger C, Antunes C, Pereira MS, Leke R, Wofchuk ST, Elisabetsky E, Souza DO (2009) Spinal mechanisms of antinociceptive action caused by guanosine in mice. Eur J Pharmacol 613:46–53PubMedCrossRefGoogle Scholar
  209. Schulte G, Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15:813–827PubMedCrossRefGoogle Scholar
  210. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 29:647–654PubMedCrossRefGoogle Scholar
  211. Shen H, Chen GJ, Harvey BK, Bickford PC, Wang Y (2005) Inosine reduces ischemic brain injury in rats. Stroke 36:654–659PubMedCrossRefGoogle Scholar
  212. Sperlágh B, Vizi ES (2011) The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Curr Top Med Chem 11:1034–1046PubMedCrossRefGoogle Scholar
  213. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ (1996) Citicoline improves verbal memory in aging. Arch Neurol 53:441–448PubMedCrossRefGoogle Scholar
  214. Stone TW (2002) Purines and neuroprotection. Adv Exp Med Biol 513:249–280PubMedCrossRefGoogle Scholar
  215. Svenningsson P, Hall H, Sedvall G, Fredholm BB (1997) Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 27:322–335PubMedCrossRefGoogle Scholar
  216. Teather LA, Wurtman RJ (2003) Dietary cytidine (5’)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 27:711–717PubMedCrossRefGoogle Scholar
  217. Teather LA, Wurtman RJ (2005) Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learn Mem 12:39–43PubMedCrossRefGoogle Scholar
  218. Teather LA, Wurtman RJ (2006) Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr 136:2834–2837PubMedGoogle Scholar
  219. Togha M, Akhondzadeh S, Motamedi M, Ahmadi B, Razeghi S (2007) Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch Med Res 38:313–316PubMedCrossRefGoogle Scholar
  220. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F (2008) Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 30:744–766PubMedCrossRefGoogle Scholar
  221. Tort AB, Mantese CE, dos Anjos GM, Dietrich MO, Dall’Igna OP, Souza DO, Lara DR (2004) Guanosine selectively inhibits locomotor stimulation induced by the NMDA antagonist dizocilpine. Behav Brain Res 154:417–422PubMedCrossRefGoogle Scholar
  222. Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1–22PubMedCrossRefGoogle Scholar
  223. Traversa U, Bombi G, Di Iorio P, Ciccarelli R, Werstiuk ES, Rathbone MP (2002) Specific [(3)H]-guanosine binding sites in rat brain membranes. Br J Pharmacol 135:969–976PubMedCrossRefGoogle Scholar
  224. Tsai SJ, Hong CJ, Hou SJ, Yen FC (2006) Association study of adenosine A2a receptor (1976 C  >  T) genetic polymorphism and mood disorders and age of onset. Psychiatr Genet 16:185PubMedCrossRefGoogle Scholar
  225. Tucker AL, Linden J (1993) Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27:62–67PubMedCrossRefGoogle Scholar
  226. Van der Beek EM, Kamphuis P (2008) The potential role of nutritional components in the management of Alzheimer’s Disease. Eur J Pharmacol 585:197–207PubMedCrossRefGoogle Scholar
  227. Van Rompay AR, Johansson M, Karlsson A (2003) Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Therapeut 100:119–139CrossRefGoogle Scholar
  228. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA (2000) [(3)H]MRE 3008 F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol 57:968–975PubMedGoogle Scholar
  229. Vinadé ER, Schmidt AP, Frizzo ME, Izquierdo I, Elisabetsky E, Souza DO (2003) Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res 977:97–102PubMedCrossRefGoogle Scholar
  230. Volonté C, D’Ambrosi N (2009) Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J 276:318–329PubMedCrossRefGoogle Scholar
  231. Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003) Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 3:427–443PubMedCrossRefGoogle Scholar
  232. Von Lubitz DK (2001) Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert Opin Investig Drugs 10:619–632CrossRefGoogle Scholar
  233. Wardas J (2002) Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 54:313–326PubMedGoogle Scholar
  234. Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC (2010) Identification of targets and new developments in the treatment of multiple sclerosis–focus on cladribine. Drug Des Devel Ther 4:117–126PubMedGoogle Scholar
  235. Weber G, Prajda N (1994) Targeted and non-targeted actions of anti-cancer drugs. Adv Enzyme Regul 34:71–89PubMedCrossRefGoogle Scholar
  236. Weber G, Ichikawa S, Nagai M, Natsumeda Y (1990) Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Commun 2:129–133PubMedGoogle Scholar
  237. Weerts EM, Griffiths RR (2003) The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl) 168:155–163CrossRefGoogle Scholar
  238. Weyrich AS, Skalabrin EJ, Kraiss LW (2009) Targeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamole. Am J Ther 16:164–170PubMedCrossRefGoogle Scholar
  239. Wiesner JB, Ugarkar BG, Castellino AJ, Barankiewicz J, Dumas DP, Gruber HE, Foster AC, Erion MD (1999) Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther 289:1669–1677PubMedGoogle Scholar
  240. Willis RC, Carson DA, Seegmiller JE (1978) Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 75:3042–3044PubMedCrossRefGoogle Scholar
  241. Willuhn I, Wanat MJ, Clark JJ, Phillips PE (2010) Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci 3:29–71PubMedCrossRefGoogle Scholar
  242. Wurtman RJ, Regan M, Ulus I, Yu L (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 60:989–992PubMedCrossRefGoogle Scholar
  243. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29:59–87PubMedCrossRefGoogle Scholar
  244. Xu K, Bastia E, Schwarzschild M (2005) Therapautic potential of adenosine A2A receptor antagonists in Parkinson’s disease. Pharmacol Ther 105:267–310PubMedCrossRefGoogle Scholar
  245. Yegutkin GG (2008) Nucleotide- and nucleoside converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783:673–694PubMedCrossRefGoogle Scholar
  246. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC (2004) Antiretrovirals, part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 45:524–535PubMedCrossRefGoogle Scholar
  247. Zaza A (2002) CVT-510 (CV Therapeutics). Curr Opin Investig Drugs 3:96–100PubMedGoogle Scholar
  248. Zhao Q, Marolewski A, Rusche JR, Holmes GL (2006) Effects of uridine in models of epileptogenesis and seizures. Epilepsy Res 70:73–82PubMedCrossRefGoogle Scholar
  249. Zhao Q, Shatskikh T, Marolewski A, Rusche JR, Holmes GL (2008) Effects of uridine on kindling. Epilepsy Behav 13:47–51PubMedCrossRefGoogle Scholar
  250. Zimmermann H (1996) Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog Neurobiol 49:589–618PubMedCrossRefGoogle Scholar
  251. Zoref-Shani E, Bromberg Y, Lilling G, Gozes I, Brosh S, Sidi Y, Sperling O (1995) Developmental changes in purine nucleotide metabolism in cultured rat astroglia. Int J Dev Neurosci 13:887–896PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of ZoologyUniversity of West HungarySzombathelyHungary
  2. 2.Neuromorphological and Neuroendocrine Research Laboratory, Department of Anatomy, Histology and EmbryologySemmelweis University and the Hungarian Academy of SciencesBudapestHungary

Personalised recommendations